地塞米松玻璃體腔植入劑異位于前房一例_Chinese Journal of Ocular Fundus Diseases

Authors：

吳頔 , 任新軍 ,  李筱榮

天津醫科大學眼科醫院、眼視光學院、眼科研究所，天津市視網膜功能與疾病重點實驗室 300384;

Corresponding?author：

李筱榮, Email: xiaorli@163.com

Keywords：

地塞米松; 遲效制劑; 病例報告; 異位; 前房

DOI：

10.3760/cma.j.issn.1005-1015.2019.06.019

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 吳頔, 任新軍, 李筱榮. 地塞米松玻璃體腔植入劑異位于前房一例. Chinese Journal of Ocular Fundus Diseases, 2019, 35(6): 608-609. doi: 10.3760/cma.j.issn.1005-1015.2019.06.019 Copy

1.	Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema[J]. Retina, 2009, 29(1): 46-51. DOI: 10.1097/IAE.0b013e318188c814.
2.	Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration:risk factors, complications, and management strategies[J]. Ophthalmology, 2014, 121(1): 67-71. DOI: 10.1016/j.ophtha.2013.06.033.
3.	Rezar-Dreindl S, Eibenberger K, Pollreisz A, et al. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion[J]. Acta Ophthalmol, 2017, 95(2): 119-127. DOI: 10.1111/aos.13152.
4.	Campochiaro PA, Hafiz G, Mir TA, et al. Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for Retinal Vein Occlusion (ORVO) Study[J]. Am J Ophthalmol, 2015, 160(2): 313-321. DOI: 10.1016/j.ajo.2015.04.025.
5.	黎曉新, 王寧利, 梁小玲, 等. 地塞米松玻璃體腔植入劑治療中國患者視網膜靜脈阻塞繼發黃斑水腫的安全性和有效性:隨機、假注射對照、多中心研究[J]. 中華眼底病雜志, 2018, 34(3): 212-220. DOI: 10.3760/cma.j.issn.1005-1015.2018.03.003.Li XX, Wang NL, Liang XL, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusionin Chinese patients: randomized,sham-controlled,multicenter study[J]. Chin J Ocul Fundus Dis, 2018, 34(3): 212-220. DOI: 10.3760/cma.j.issn.1005-1015.2018.03.003.
6.	Bansal R, Bansal P, Kulkarni P, et al. Wandering Ozurdex(R) implant[J]. J Ophthalmic Inflamm Infect, 2012, 2(1): 1-5. DOI: 10.1007/s12348-011-0042-x.
7.	Vela JI, Crespí J, Andreu D. Repositioning of dexamethasone intravitreal implant (Ozurdex^?) migrated into the anterior chamber[J]. Int Ophthalmol, 2012, 32(6): 583-584. DOI: 10.1007/s10792-012-9604-7.
8.	Pardo-López D, Francés-Mu?oz E, Gallego-Pinazo R, et al. Anterior chamber migration of dexametasone intravitreal implant (Ozurdex^?)[J]. Graefe's Arch Clin Exp Ophthalmol, 2012, 250(11): 1703-1704. DOI: 10.1007/s00417-011-1802-x.
9.	Gullapalli VK, DiLoreto DA. Migration of intravitreal dexamethasone implant to anterior chamber[J]. Retin Cases Brief Rep, 2013, 7(1): 111-113. DOI: 10.1097/ICB.0b013e31826f08b0.
10.	Rahimy E, Pitcher Ⅲ JD, Abbey AM, et al. No-touch removal of anterior segment-migrated dexamethasone implant[J]. Retina, 2015, 35(11): 2414-2416. DOI: 10.1097/IAE.0000000000000753.

1. Haller JA, Dugel P, Weinberg DV, et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema[J]. Retina, 2009, 29(1): 46-51. DOI: 10.1097/IAE.0b013e318188c814.
2. Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration:risk factors, complications, and management strategies[J]. Ophthalmology, 2014, 121(1): 67-71. DOI: 10.1016/j.ophtha.2013.06.033.
3. Rezar-Dreindl S, Eibenberger K, Pollreisz A, et al. Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion[J]. Acta Ophthalmol, 2017, 95(2): 119-127. DOI: 10.1111/aos.13152.
4. Campochiaro PA, Hafiz G, Mir TA, et al. Pro-permeability factors after dexamethasone implant in retinal vein occlusion: the Ozurdex for Retinal Vein Occlusion (ORVO) Study[J]. Am J Ophthalmol, 2015, 160(2): 313-321. DOI: 10.1016/j.ajo.2015.04.025.
5. 黎曉新, 王寧利, 梁小玲, 等. 地塞米松玻璃體腔植入劑治療中國患者視網膜靜脈阻塞繼發黃斑水腫的安全性和有效性:隨機、假注射對照、多中心研究[J]. 中華眼底病雜志, 2018, 34(3): 212-220. DOI: 10.3760/cma.j.issn.1005-1015.2018.03.003.Li XX, Wang NL, Liang XL, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusionin Chinese patients: randomized,sham-controlled,multicenter study[J]. Chin J Ocul Fundus Dis, 2018, 34(3): 212-220. DOI: 10.3760/cma.j.issn.1005-1015.2018.03.003.
6. Bansal R, Bansal P, Kulkarni P, et al. Wandering Ozurdex(R) implant[J]. J Ophthalmic Inflamm Infect, 2012, 2(1): 1-5. DOI: 10.1007/s12348-011-0042-x.
7. Vela JI, Crespí J, Andreu D. Repositioning of dexamethasone intravitreal implant (Ozurdex^?) migrated into the anterior chamber[J]. Int Ophthalmol, 2012, 32(6): 583-584. DOI: 10.1007/s10792-012-9604-7.
8. Pardo-López D, Francés-Mu?oz E, Gallego-Pinazo R, et al. Anterior chamber migration of dexametasone intravitreal implant (Ozurdex^?)[J]. Graefe's Arch Clin Exp Ophthalmol, 2012, 250(11): 1703-1704. DOI: 10.1007/s00417-011-1802-x.
9. Gullapalli VK, DiLoreto DA. Migration of intravitreal dexamethasone implant to anterior chamber[J]. Retin Cases Brief Rep, 2013, 7(1): 111-113. DOI: 10.1097/ICB.0b013e31826f08b0.
10. Rahimy E, Pitcher Ⅲ JD, Abbey AM, et al. No-touch removal of anterior segment-migrated dexamethasone implant[J]. Retina, 2015, 35(11): 2414-2416. DOI: 10.1097/IAE.0000000000000753.

Chinese Journal of Ocular Fundus Diseases

地塞米松玻璃體腔植入劑異位于前房一例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content